Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Reducing Drug Side-Effects In Pain Relief: New Research
They are a group of drugs which millions of people rely on to keep pain at bay but they can have unwanted side-effects which are sometimes more serious than the original health problem. Now scientists at The University of Nottingham are taking part in the largest-ever study on the safety of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) that has ever been performed.
generic viagra online
Long-Term Care Program Would Provide Revenue - At First
A long-term care program could produce some needed dollars, at least in the short range, CQ Politics reports: "A new insurance program for long-term care that Democrats have included in a Senate health overhaul bill would produce about $58 billion in revenue for the government over the next 10 years, according to the Congressional Budget Office, helping to offset the cost of the legislation. Democrats acknowledge that spending in the long-term care program would increase after 10 years and that it likely would not remain a very profitable enterprise for the government. It is even possible, they say, that the program could become insolvent; in that case, the secretary of Health and Human Services would be authorized to close its enrollment. "The CBO says that premiums would have to rise significantly higher than Democrats have assumed for the program to remain financially sound."
News of the day
They Are Young And Need The Job: A Second Chance For Dangerous T-cells
The immune system"s T-cells react to foreign protein fragments and therefore are crucial to combating viruses and bacteria. Errant cells that attack the body"s own material are in most cases driven to cell death. Some of these autoreactive T-cells, however, undergo a kind of reeducation to become "regulatory T-cells" that keep other autoreactive T-cells under control. A group led by immunologist Professor Ludger Klein of LMU Munich has now shown that the developmental stage of an autoreactive T-cell is decisive to its ultimate destiny. Young autoreactive T cells are very readily reeducated into regulatory T-cells. Under identical conditions, however, older T cells become fully activated and can cause damage they are in a way resistant to reeducation. "We now intend to study at the molecular level what makes a T-cell accessible for reeducation," said Klein, "because then it may be possible to convert even normal adult T-cells, which can be obtained easily and in great numbers from blood. Possibly, they could then be used as regulatory T-cells in therapies for autoimmune diseases such as type-1 diabetes or multiple sclerosis: these are diseases that are triggered by uncontrolled autoreactive T-cells." (PNAS, 10 June 2009)
Nutrition

Genetic Immunity, InPlay Completes Patient Enrollment In Phase II Trial Of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate

Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary"s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis. Genetic Immunity is pleased to announce completion of patient enrollment in the Company"s Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir Patch in treatment-naç¯ve HIV-1-infected patients. The study is conducted in Hamburg, Germany with a total of thirty-six patients. "We are very happy with completion of patient enrollment in this seminal trial because it allows us to conclude the immunization schedule in this year. This trial has a unique design to investigate DermaVir Patch as mono-immunotherapy in HIV-infected individuals who are not treated with antiretroviral drugs. We are very excited to learn how our immune therapeutic nanomedicine affects the immune system and disease of this patient population. With this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV," commented Julianna Lisziewicz, CEO of Genetic Immunity. This novel plasmid DNA-based nanomedicine vaccine candidate, DermaVir Patch, has been under development in the last ten years. Phase I trial showed preliminary safety and tolerability and induction of memory T-cell immunity in all HIV-1-infected individuals. DermaVir is based on a single plasmid DNA capable to express most HIV antigens and to form a virus-like particle (VLP+). Plasmid DNA is formulated with a polymer to mimic a pathogen. DermaVir enters into the body via the Langerhans cells of the skin and induces memory immune responses in the lymph nodes. The primary outcome of this phase II study measures safety and tolerability of DermaVir Patch, while secondary outcome includes HIV-1 RNA measurements to assess the antiretroviral activity of the DermaVir Patch, changes in CD4+, CD8+ T-cell counts and HIV-specific immunogenicity during DermaVir Patch treatment. The study randomized patients into one of 6 arms: Arm 1 patients will receive low dose DermaVir patch (0.2 mg DNA, n=9); Arm 2 patients will receive low dose placebo patch (n=3); Arm 3 patients will receive medium dose DermaVir patch (0.4 mg DNA, n=9); Arm 4 patients will receive medium dose placebo patch (n=3); Arm 5 patients will receive high dose DermaVir patch (0.8 mg DNA, n=9); Arm 6 patients will receive high dose placebo patch (n=3). Immunization will be done on days 0, 42, 84, and 126. The total number of patches that a patient will receive throughout the study will be 8, 16, or 32 in the low, medium, and high dose arms, respectively. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thighs. The same skin sites might be used for all patch immunizations that last for 3 hours. Patients will be on-study for 282 weeks. The immunizations will be administered over an 18-week period with an identical follow up schedule continuing until week 24; patients will be followed for an additional 24 weeks for additional safety and immunogenicity evaluations. An additional 234 weeks safety follow-up will be performed including chemistry and hematology assessments and physical examinations. For more information please visit the Company"s official website at http://www.geneticimmunity.com About Genetic Immunity Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. Power of the Dream Ventures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009